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sFlt-1 (soluble Flt-1) potently inhibits angiogenesis by binding
extracellularly to VEGF (vascular endothelial growth factor).
In the present paper, we report that hypoxia down-regulates
sFlt-1 expression in HMVECs (human microvascular endothelial
cells), a constituent of microvessels where angiogenesis occurs.
Hypoxia (5–1% O2) increased VEGF expression in HMVECs.
In contrast, the levels of sFlt-1 mRNA and protein in HMVECs
decreased signiﬁcantly as the O2 concentration fell, whereas
mFlt-1 (membrane-bound Flt-1) mRNA and protein remained
unchanged. This suggested that hypoxia selectively regulates
alternative 3
 -end processing of sFlt-1 pre-mRNA. We have also
demonstrated that sFlt-1 overexpression in lentiviral-construct-
infected HMVECs counteracted VEGF-induced endothelial cell
growth. We next identiﬁed cis-elements involved in sFlt-1 mRNA
processing in HMVECs using a human Flt-1 minigene and
found that two non-contiguous AUUAAA sequences function as
the poly(A) signal. Furthermore, we identiﬁed a cis-element in
intron 13 that regulates sFlt-1 mRNA processing. Mutagenesis
of the U-rich region in intron 13 caused a signiﬁcant decrease
in the soluble-form/membrane-form RNA ratio in the minigene-
transfected HMVECs. These results suggest that decreased
sFlt-1 expression due to hypoxia contributes to hypoxia-
induced angiogenesis and reveals a novel mechanism regulating
angiogenesis by alternative mRNA 3
 -end processing.
Key words: angiogenesis, hypoxia, mRNA 3
 -end processing,
soluble Flt-1, vascular endothelial cell, vascular endothelial
growth factor (VEGF).
INTRODUCTION
Angiogenesis is the process by which new vascular networks are
formed from pre-existing capillaries. This process is essential for
embryogenesis, development and wound repair [1], and plays an
important role in the progression of diseases such as cancers,
diabetic retinopathy and rheumatoid arthritis [1]. A balance
between endogenous positive and negative regulatory molecules
strongly inﬂuences angiogenesis [2]. VEGF (vascular endothelial
growth factor) is a central regulator of the angiogenic process
in both physiological and pathological conditions [1]. VEGF
stimulates proliferation and tube formation of vascular ECs
(endothelial cells) by binding to speciﬁc cell-surface receptors.
VEGF is expressed in ECs, a constituent of microvessels where
angiogenesis occurs, and is up-regulated under hypoxia, which
is the principal inducer of angiogenesis [3,4]. In addition, ECs
express several angiostatic factors such as sFlt-1 (soluble Flt-
1)/sVEGFR-1 [soluble VEGFR (VEGF receptor)-1], soluble
neuropilin-1, thrombospondin and endostatin [5,6]. These results
suggest that MVECs (microvascular ECs) employ both autocrine
and paracrine loops which co-express VEGF and its antagonists
to regulate angiogenesis.
sFlt-1, a potent anti-angiogenic factor, is produced by the
gene encoding cell-surface mFlt-1 (membrane-bound Flt-1) by
mRNA alternative 3
 -end processing. sFlt-1 is composed of the
extracellular domain of mFlt-1 and is capable of trapping its
ligand VEGF. VEGF binds to Flt-1 with a much greater afﬁnity
(dissociation constant, approximately 2–10 pM) than that for
KDR (kinase insert domain-containing receptor; also referred
to as VEGFR-2), which is the major functional receptor for
VEGF [7,8]. sFlt-1 regulates various physiological processes
in tissues. For example, sFlt-1 expression maintains corneal
avascularity [9], and spatially regulated sFlt-1 expression guides
vessel sprouting and morphogenesis in developing blood vessels
[10].ExcesscirculatingsFlt-1hasbeenimplicatedintheaetiology
of endothelial dysfunction, hypertension and proteinuria in pre-
eclampsia [11], and sFlt-1 overexpression has been reported to
inhibit tumour growth and angiogenesis [12].
Although VEGF is known to be up-regulated in various tissues
and cell types under hypoxia [3,4,13], the mechanisms that
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regulate sFlt-1 expression in microvessels under these conditions
havenotyetbeenfullyclariﬁed.Furthermore,therelevantﬁndings
available in this regard are conﬂicting [14–16].
In the present study, we have investigated the regulation of
sFlt-1 expression under hypoxia in primary cultured HMVECs
(human MVECs). We have found that hypoxia down-regulates
sFlt-1 expression, but not mFlt-1 expression, by mechanisms
that may involve alternative 3
 -end processing of sFlt-1 mRNA.
Furthermore,wehaveidentiﬁedthecis-elementsthatregulatethis
process.
EXPERIMENTAL
Cells
HMVECs isolated from neonatal dermis (Cascade Biologics)
were maintained in HuMedia-EB2 medium supplemented
with 5% (v/v) FBS (fetal bovine serum), 5 ng/ml bFGF
(basic ﬁbroblast growth factor), 10 μg/ml heparin, 10 ng/ml
EGF (epidermal growth factor), 1 μg/ml hydrocortisone and
39.3 μg/ml dibutyryl cAMP, according to the manufacturer’s
instructions (Kurabo). Hypoxia and proliferation experiments
employing HMVECs were performed using HuMedia-EB2
medium supplemented with 0.1% FBS, 5 ng/ml bFGF and
10 μg/ml heparin (assay medium). Brieﬂy, cells were incubated
for24 hinaCO2/tri-gasincubator(Astec)containingamixtureof
5% (v/v) CO2 and 1–10% (v/v) O2 balanced with N2. The cells
wereviableafter24and48 hofexposuretohypoxiaandcontinued
to proliferate. Recombinant human VEGF (BD Biosciences) or
DMOG (dimethyloxaloylglycine; Sigma–Aldrich) were added to
the culture medium at the indicated concentration. HEK-293TN
cells [HEK (human embryonic kidney)-293 cells expressing the
large T-antigen of SV40 (simian virus 40) and the neomycin-
resistance gene] (System Biosciences) were maintained in
DMEM (Dulbecco’s modiﬁed Eagle’s medium; Sigma–Aldrich)
supplemented with 10% (v/v) FBS, 100 units/ml penicillin and
100 μg/ml streptomycin.
RT (reverse transcription)–PCR
Total RNA was isolated from HMVECs using the RNeasy
Mini Kit (Qiagen) and was subjected to RT–PCR using the
SuperScript® III One-Step RT–PCR System with Platinum® Taq
DNA Polymerase (Life Technologies). The oligodeoxyribonuc-
leotide primers employed are listed in Supplementary Table S1
(at http://www.BiochemJ.org/bj/436/bj4360399add.htm). Ampli-
ﬁcationconditionswereasfollows:temperaturesandtimeperiods
for melting, annealing and extension were 95◦C for 15 s, 60◦C
for 30 s and 68◦C for 30 s respectively. The conditions (amounts
of RNA templates and cycle numbers for ampliﬁcation) used
resulted in linear ampliﬁcation kinetics [3,4]. An aliquot of each
reaction mixture was electrophoresed on a 2% (w/v) agarose gel
and stained with ethidium bromide.
Real-time RT–PCR
Real-time RT–PCR was performed to determine relative mRNA
levels using the StepOnePlus Real-Time System (Life Technolo-
gies).mFlt-1,VEGFandKDRmRNAlevelsweremeasuredusing
TaqMan Gene Expression Assays (Hs00176573_m1 for mFlt-
1, Hs00900055_m1 for VEGF and Hs00911700_m1 for KDR;
Life Technologies) and the TaqMan® RNA-to-CT
TM 1-Step
Kit (Life Technologies), according to the manufacturer’s
instructions. The sFlt-1 mRNA level was measured using gene-
speciﬁc primers (5
 -TTGGGACTGTGGGAAGAAAC-3
  and 5
 -
TTGGAGATCCGAGAGAAAACA-3
 )andtheOneStepSYBR®
PrimeScript® RT–PCR Kit (Takara). β-Actin (human ACTB
endogenous control; Life Technologies) was used as the internal
control. Gene expression levels were analysed by plotting ﬁve-
point serial standard curves using total RNA from HMVECs
cultured under normoxia.
Western blotting
HMVECs were cultured under hypoxia (1 or 2.5% O2)o r
normoxiaintheassaymedium.Thecellswerecollectedandlysed
with loading buffer [17]. Samples were electrophoresed on a 5–
20% (w/v) polyacrylamide gradient gel (e-PAGEL; ATTO) and
transferred on to an Immobilon-P (Millipore) membrane using
the Trans-Blot SD Cell (Bio-Rad Laboratories). After treatment
with Odyssey blocking buffer (LI-COR Biosciences) for 1 h at
room temperature (25◦C), the membrane was incubated at room
temperature for 1 h with a rabbit anti-Flt-1 antibody (Y103;
Epitomics) and a mouse anti-β-actin monoclonal antibody (AC-
74; Sigma–Aldrich). The membrane was then incubated at room
temperaturefor1 hwithIRDye800CWanti-(rabbitIgG)antibody
andIRDye680anti-(mouseIgG)antibody(LI-CORBiosciences),
and visualized using an Odyssey IR imaging system (LI-COR
Biosciences).
ELISA
HMVECs were cultured under hypoxia (1 or 2.5% O2)o r
normoxia in the assay medium. Protease inhibitors (Complete
Mini; Roche Diagnostics) were added to the conditioned medium
and centrifuged at 10000 g for 15 min at 4◦C. The supernatants
werecollectedandassayedforsFlt-1usingtheQuantikineHuman
Soluble VEGFR1/Flt-1 Immunoassay Kit (R&D Systems) with
recombinant human sFlt-1 and polyclonal antibodies against
human sFlt-1. HMVEC-conditioned medium and cell lysates
were analysed for VEGF using the Quantikine Human VEGF
Immunoassay Kit (R&D Systems) with recombinant human
VEGF165 and anti-VEGF polyclonal antibodies. For preparation
of HMVEC cell lysates, cells in 75-cm
2 ﬂasks were washed with
PBS and removed with a scraper after the addition of 1 ml of
lysis buffer [PBS containing 1% (w/v) Nonidet P40 and protease
inhibitors]. Suspensions were then sonicated and centrifuged at
10000 g for 10 min at 4◦C, and the supernatants were used for
analysis.
Construction of lentiviral vectors and transduction of HMVECs
Human sFlt-1 and hnRNP (heterogeneous nuclear ribonucleo-
protein) D cDNAs were generated from HMVEC template
RNAs using the primers listed in Supplementary Table S2
(at http://www.BiochemJ.org/bj/436/bj4360399add.htm) and the
TaKaRa High Fidelity RNA PCR Kit; the 5
 -a n d3
 -primers
contained EcoRI and NotI sites respectively. The ampliﬁed
cDNAs were digested with EcoRI and NotI and inserted into
thepCDH-CMV-MCS-EF1-copGFPvector(SystemBiosciences)
that had been digested using the same restriction enzymes.
Recombinant plasmid DNAs were puriﬁed using the EndoFree
Plasmid Maxi Kit (Qiagen) and were subjected to nucleotide
sequencing to verify their authenticity. Pseudoviral particles were
generated by co-transfecting the pCDH vector and pPACKH1
Packaging Plasmid Mix (System Biosciences) into HEK-293TN
cells using Lipofectamine
TM (Life Technologies) and Plus
TM
Reagent (Life Technologies). At 1 day prior to infection,
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Figure 1 Hypoxia down-regulates sFlt-1 mRNA expression in HMVECs
(A)ExpressionofsFlt-1,mFlt-1,VEGFandβ-actinmRNAsinHMVECsundernormoxiaorhypoxia.TotalRNAsfromHMVECsculturedfor24hundertheindicatedoxygentensionswereanalysedby
RT–PCR using primers listed in Supplementary Table S1 (at http://www.BiochemJ.org/bj/436/bj4360399add.htm). An aliquot of each RT–PCR mixture was electrophoresed on a 2% (w/v) agarose
gel and visualized by ethidium bromide staining. (B) sFlt-1, mFlt-1 and β-actin mRNA expression in HMVECs in the presence of VEGF. Total RNAs from HMVECs cultured for 24h in the presence
of the indicated concentrations of VEGF were analysed by RT–PCR. (C and D) Determination of the sFlt-1/mFlt-1 mRNA ratio under hypoxia. (C) Total RNAs from HMVECs cultured under hypoxia
(2.5% O2) orin thepresenceof100ng/mlVEGFwereanalysedbyRT–PCRusingtherespectivehuman-speciﬁcprimersfor sFlt-1 and mFlt-1 mRNAsin the sametube.KDR(VEGFR-2)andβ-actin
mRNA levels were also analysed by RT–PCR. (D) sFlt-1/mFlt-1 mRNA ratio. Quantiﬁcation of the signal intensities of sFlt-1 and mFlt-1 mRNAs was performed using the public domain ImageJ
program. Values are means+ −S.D. (n=4). Statistical signiﬁcance was determined using a Student’s t test for unpaired data. *P <0.05 and ***P <0.001.
HMVECs were seeded at a density of 1–2×10
5 cells/well in
a six-well plate and then infected with the lentiviral constructs in
the presence of 5 μg/ml polybrene (Sigma–Aldrich). After 48 h,
the expression of sFlt-1 and hnRNP D was determined by RT–
PCR.
Cell proliferation assays
Lentiviral-construct-infected HMVECs were seeded at a density
of 2×10
3 cells/well in a 96-well plate in 0.1 ml of assay
medium.Thecellswereincubatedfor24 hat37◦C.Recombinant
human VEGF (1 ng/ml) was then added and the cultures were
incubated for another 3 days. After incubation, cell proliferation
was evaluated by the cellular reduction of the tetrazolium salt
WST-8 to formazan (Cell Counting Kit-8; Dojindo Laboratories).
Construction and expression of Flt-1 minigenes
An Flt-1 minigene (see Figure 6A) was constructed by inserting
human Flt-1 gene fragments from exons 12 to 14, excluding
the parts of introns 12 and 13 (nucleotide residues 98061–
99023, 104664–106441 and 109486–110296 of GenBank®
accession number NC_000013) into the pCI-neo mammalian
expression vector (Promega). PCR-ampliﬁed fragments using
the three primer pairs listed in Supplementary Table S2
were digested using the indicated restriction enzymes and
inserted into the XhoI/NotI-digested pCI-neo vector. Sequence
motifs for RNA-binding proteins in the Flt-1 minigene were
searched using the ‘Splicing Rainbow’ at EBI database
(http://www.ebi.ac.uk/asd-srv/wb.cgi?method=8), and mutations
were generated using the GeneTailor Site-Directed Mutagenesis
System (Life Technologies), according to the manufacturer’s
instructions, with the primers listed in Supplementary Table
S1. Nucleotide sequencing veriﬁed that the mutations had been
correctly introduced. HMVECs were transfected with these Flt-1
minigenes and the hnRNP D expression vector using jetPEI
TM-
HUVEC (Polyplus Transfection). After 24 h, Flt-1 expression
from the minigenes was determined by RT–PCR.
Statistical analysis
Statistical signiﬁcance of the data was determined using a
Student’s t-test for unpaired data. Multiple comparisons were
analysed by one-way ANOVA with Dunnett’s and Bonferroni’s
post-hoc tests for signiﬁcance using the Graphpad Prism 4
software. Statistical signiﬁcance was deﬁned as
*P<0.05,
**P<0.01 or
***P<0.001.
RESULTS
Effect of hypoxia on sFlt-1 and mFlt-1 mRNA levels in HMVECs
RT–PCR analysis demonstrated that HMVECs expressed both
sFlt-1 and mFlt-1 mRNAs (Figure 1). VEGF mRNA levels
increased signiﬁcantly as the O2 concentration fell to 5% and
increased further at 2.5 and 1% (Figure 1A). This result indicates
that HMVECs were appropriately cultured under hypoxia [3,4].
In contrast, sFlt-1 mRNA levels decreased signiﬁcantly as the
O2 concentration fell to 2.5% and decreased further to 1%,
whereas mFlt-1 mRNA levels in HMVECs remained unchanged
under hypoxia (Figure 1A). Since VEGF mRNA levels increased
under hypoxia (Figure 1A), we examined the effects of VEGF
on sFlt-1 and mFlt-1 mRNA levels (Figure 1B). Both sFlt-1
and mFlt-1 mRNA levels remained unchanged at low VEGF
concentrations (0.1–10 ng/ml), but increased signiﬁcantly at an
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Figure 2 Real-time RT-PCR analysis of sFlt-1, mFlt-1, KDR and VEGF
mRNAs in HMVECs under normoxia or hypoxia
Total RNAs were isolated from HMVECs cultured for 24h under normoxia or hypoxia (2.5%
O2). Relative sFlt-1 (A), mFlt-1 (B), VEGF (C)a n dK D R( D) mRNA levels were determined by
real-time RT–PCR as described in the Experimental section. Values are means+ −S.D. (n=3).
StatisticalsigniﬁcancewasdeterminedusingaStudent’st testforunpaireddata.***P <0.001.
extremely high VEGF concentration (100 ng/ml). We examined
the VEGF protein levels in conditioned medium and HMVEC
cell lysates that had been cultured under normoxia and hypoxia (1
and 2.5% O2) by ELISA. VEGF in cell lysates was undetectable
under normoxia, and its protein levels increased to 27 and 31
pg/mg of protein under 2.5% and 1% O2 respectively. VEGF in
the conditioned medium was undetectable under all conditions.
The VEGF levels were much lower than those that could affect
Flt-1 expression. These results indicate that the hypoxia-induced
increase in VEGF probably did not affect sFlt-1 mRNA levels.
We then determined relative sFlt-1 and mFlt-1 mRNA levels
by simultaneous PCR-ampliﬁcation using RNAs from HMVECs
cultured under normoxia and hypoxia (2.5% O2) in the same
tube using the primer pairs described in Supplementary Table
S1 (Figure 1C). Densitometric analyses revealed that hypoxia
caused signiﬁcant decreases in the sFlt-1/mFlt-1 mRNA ratio,
whereas the ratio remained unchanged or slightly increased in
the presence of VEGF (Figure 1D). These results suggest that
hypoxia regulates sFlt-1 mRNA levels at the level of alternative
processing of its pre-mRNA. In comparison, KDR (VEGFR-2)
mRNA levels remained unchanged under hypoxia (Figure 1C).
We also determined relative sFlt-1, mFlt-1, KDR and VEGF
mRNA levels by real-time PCR using the same RNAs described
inFigure1.AsshowninFigure2,theresultswereconsistentwith
those obtained by RT–PCR (Figure 1).
To determine whether sFlt-1 mRNA and protein levels were
co-ordinately expressed under normoxia and hypoxia (2.5%
O2), we determined sFlt-1 protein levels secreted in the culture
medium by ELISA (Figure 3A). sFlt-1 mRNA levels decreased
to approximately 60% under hypoxia (Figures 1D and 2A), and
Figure 3 sFlt-1 and mFlt-1 protein levels under hypoxia
(A) Conditioned medium was collected from cells cultured for 24h under normoxia or hypoxia
(2.5%O2)andsFlt-1proteinlevelswerequantiﬁedbyELISA.Valuesaremeans+ −S.D.(n=3).
StatisticalsigniﬁcancewasdeterminedusingaStudent’st testforunpaireddata.***P <0.001.
(B) Western blot analysis of mFlt-1 protein in cell lysates prepared from HMVECs cultured as
described in (A).
sFlt-1proteinlevels(6.6 ng/10
6 cells,3.4 ng/ml)alsodecreasedto
approximately 40% (2.8 ng/10
6 cells, 1.2 ng/ml) under hypoxia
(Figure 3A). mFlt-1 protein levels remained unchanged under
hypoxia (Figure 3B) corresponding to mFlt-1 mRNA levels
(Figures 1A and 2B).
Effect of DMOG on sFlt-1 and mFlt-1 mRNA levels in HMVECs
HIF (hypoxia-inducible factor)-1 plays a central role during
the response to hypoxia [18]. Hypoxia stabilizes HIF-1α by
inhibiting HIF-PHD (prolyl hydroxylase), which leads to HIF-
1α degradation. Stabilized HIF-1α dimerizes with HIF-1β and
activates the expression of multiple hypoxia-responsive genes,
such as VEGF and erythropoietin.
To determine whether HIF-1 was involved in the decrease
in sFlt-1 mRNA levels in hypoxic HMVECs, we examined the
effect of a PHD inhibitor, DMOG [19], on Flt-1 expression. As
shown in Figure 4, DMOG signiﬁcantly increased VEGF mRNA
levels in HMVECs, as observed under hypoxia, indicating that
DMOG stabilized HIF-1α and enhanced HIF activity. The up-
regulation of VEGF mRNA levels at DMOG concentrations of
50 and 100 μM (1.9- and 4.4-fold respectively; Figure 4E) was
comparable with those under 2.5 and 1% O2 (Figures 1A and
2C). However, sFlt-1 and mFlt-1 mRNA levels increased with
DMOG treatment (Figures 4C and 4D), but not under hypoxia
(Figures 1A, 2A and 2B). The sFlt-1/mFlt-1 mRNA ratio at 50–
100 μM DMOG remained unchanged (Figure 4B). These results
indicate that HIF-1 was not directly involved in the hypoxia-
induced decrease in sFlt-1 mRNA levels in HMVECs.
Effect of sFlt-1 overexpression on VEGF-induced HMVEC
proliferation
Because sFlt-1 can trap VEGF in the extracellular space and
thus inhibit EC growth [20], we next examined the effect of sFlt-1
overexpressiononVEGF-inducedHMVECproliferation.Human
sFlt-1 was overexpressed in HMVECs using a lentiviral vector,
and the transduction efﬁciency was nearly 100% according
to GFP (green ﬂuorescent protein) marker gene expression
(results not shown). RT–PCR conﬁrmed sFlt-1 overexpression
in transduced HMVECs (Figure 5A). Transduced HMVECs
were seeded on to a 96-well plate, incubated for 24 h and then
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Figure 4 Effect of DMOG on Flt-1 expression in HMVECs
Total RNAs were isolated from HMVECs cultured for 24h in the presence of the indicated concentration of DMOG. (A) RT–PCR analysis of mRNA levels for sFlt-1, mFlt-1 and VEGF. DMOG-treated
HMVEC RNAs were analysed by RT–PCR using the primers listed in Supplementary Table S1 (at http://www.BiochemJ.org/bj/436/bj4360399add.htm). (B) Real-time RT–PCR analysis of mRNA
levelstodeterminethesFlt-1/mFlt-1ratio.Real-timeRT-PCRanalysisofsFlt-1(C),mFlt-1(D)andVEGF(E)mRNAs.Valuesaremeans+ −S.D.(n=3).Statisticalsigniﬁcancewasdeterminedusing
a Student’s t-test for unpaired data. *P <0.05, **P <0.01 and ***P <0.001.
Figure 5 Effect of sFlt-1 overexpression on VEGF-induced HMVEC proliferation
(A) RT–PCR performed to determine sFlt-1 mRNA levels in HMVECs infected with a human sFlt-1 lentiviral construct. (B) Cell proliferation was evaluated as described in the Experimental section.
Values are means+ −S.E.M. (n=9). *P <0.05. MTT, 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H-tetrazolium bromide.
treated with recombinant human VEGF (1 ng/ml) for 3 days.
After incubation, cell proliferation was assayed as described
in the Experimental section. VEGF (1 ng/ml) moderately, but
signiﬁcantly,stimulatedtheproliferationofcontrol(emptyvector-
transduced) HMVECs (107%)( F i g u r e5 B ) .H o w e v e r ,V E G F
failed to stimulate the proliferation of sFlt-1-overexpressing
HMVECs(Figure5B).TheseresultsindicatethatsFlt-1produced
by HMVECs counteracted VEGF-induced EC proliferation in an
autocrine manner.
The Flt-1 minigene mimics alternative Flt-1 mRNA 3-end
processing in HMVECs
To investigate cis-elements potentially regulating alternative
processingofhumanFlt-1pre-mRNA,weconstructedaminigene
that contains the Flt-1 sequences from exon 12 to exon 14,
excluding segments of introns 12 and 13 (Figure 6A). We
ﬁrst identiﬁed nucleotide position 112 of intron 13 as the
major processing site of sFlt-1 mRNA in HMVECs by 3
 -rapid
ampliﬁcation of cDNA ends (results not shown); the result was
consistent with that of a previous study using HUVECs (human
umbilical vein ECs) [7]. The minigene included 1108 nucleotides
of the 5
 -region of intron 13 (Figure 6A). When the minigene
wastransfectedintoHMVECs,bothsoluble-andmembrane-form
RNAs were detected by RT–PCR (Figure 6B). The membrane
form RNA generated by normal splicing and processing with the
poly(A) signal in the vector was detected as an 850-bp band in
the RT–PCR analysis. In contrast, the soluble-form RNA, which
was cleaved and polyadenylated at the major processing site
(nucleotide position 112 of intron 13), was detected as a 651-
bp band. These results indicate that the minigene expressed both
soluble- and membrane-form RNAs by a mechanism involving
alternative mRNA processing.
Two non-contiguous AUUAAA sequences function as the poly(A)
signal for sFlt-1 mRNA processing
The human Flt-1 gene contains two AUUAAA sequences
just upstream of the major processing site of sFlt-1 mRNA
(Figure 7A). To determine the sequences that function as the
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Figure 6 Human Flt-1 minigene construct and its products
(A) Schematic representation of the human Flt-1 minigene and its soluble- and membrane-form RNAs are displayed. The shaded boxes indicate the pCI-neo vector and the black boxes
indicate the introns. The membrane-form RNA (top panel) was generated using the SV40 late poly(A) signal in the pCI-neo vector. The soluble form RNA (bottom panel) was generated
using poly(A) signals in intron 13. Arrowheads indicate the 5 -primer (5 -TCCACTCCCAGTTCAATTACAG-3 ) corresponding to vector sequences and the 3 -oligo d(T) anchor primer
(5 -CTGATCTAGAGGTACCGGATCCTTTTTTTTTTTTTTTTTV-3 ). (B) RT–PCR simultaneously detected both membrane- (850bp) and soluble- (651bp) form RNAs.
Figure 7 Mutational analyses of putative poly(A) signals for sFlt-1 mRNA
(A) The wild-type nucleotide sequence of a part of intron 13 of human Flt-1, which contains putative poly(A) signals, and those of mutations introduced into two non-contiguousAUUAAA sequences
are shown. Putative poly(A) signals are underlined. Mutated nucleotides are in bold. The arrow indicates the major cleavage site of sFlt-1 mRNA. (B) Soluble- and membrane-form RNAs were
detected by RT–PCR. Neomycin phosphotransferase(neo) mRNA expressed from the pCI-neo vector was used to normalize transfection efﬁciencies. (C) Soluble/membraneRNA ratio. Quantiﬁcation
of signal intensities was performed as described in the legend to Figure 1. The soluble/membrane RNA ratio for the wild-type minigene was assigned a value of 1. Values are means+ −S.D. (n=3).
***P <0.001.
poly(A) signal, we introduced nucleotide substitutions at the
putative poly(A) signals and examined the production of soluble-
form RNA. Mutation of the upstream AUUAAA sequence
(PAmut1) decreased soluble-form RNA levels to approximately
13% and mutation of both AUUAAA sequences (PAmut2)
decreased soluble-form RNA levels to nearly zero (Figure 7B).
Transfection efﬁciencies were normalized using neomycin
phosphotransferase (neo) mRNA, which was expressed from
the minigene, as an internal control. When the soluble-
form/membrane-form RNA ratio in the wild-type minigene was
assigned the value of 1, the ratio in PAmut1 decreased to
approximately0.1anddecreasedfurthertonearlyzeroinPAmut2
(Figure 7C). The results indicate that the upstream AUUAAA
sequence plays a major role in sFlt-1 mRNA processing,
and the downstream sequence was involved in cleavage and
polyadenylation to some extent.
A U-rich region in Flt-1 intron 13 functions as a cis-element
regulating sFlt-1 mRNA processing
To determine the potential regulatory elements controlling
alternativeprocessingofsFlt-1pre-mRNA,weintroducedaseries
oftripletnucleotidesubstitutionsatputativerecognitionsequence
motifs of RNA-binding proteins in exon and intron 13 of the Flt-1
minigene(Figure8A,mut1–8).Thesequencesofﬁvesites(mut1,
mut2, mut4, mut7 and mut8) are putative serine/arginine splicing
factor (SR) protein-binding motifs [21], and two (mut3 and mut6)
areAREs(A+U-richelements)speciﬁcforARE-bindingfactors
[22].ThemutationreplacingUUUwithAAA(mut6)dramatically
decreased soluble-form RNA levels compared with those of the
membraneform(Figure8B),suggestingthatthesequencewasin-
volved in the cleavage and polyadenylation of sFlt-1 mRNA. An-
other mutation (mut2) also decreased soluble-form RNA levels.
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Figure 8 Effects of mutagenesis of intron 13 on alternative mRNA processing
(A) Nucleotide sequences of the end of exon 13 (uppercase letters) and the 5 -portion of intron 13 (lowercase letters) of the human Flt-1 gene, and mutations introduced into the minigene. Target
nucleotides for the substitutions are in bold and underlined. (B) Soluble and membrane form RNAs were detected by RT–PCR. Quantiﬁcation of signal intensities was performed as described in the
legendtoFigure1.Thesoluble/membraneRNAratioforthewild-typeminigenewasassignedavalueof1.Valuesaremeans+ −S.D.(n=3).RT–PCRresultsforcontrolandmut6minigene-transfected
HMVECs are also shown. **P <0.01 and ***P <0.001.
The position and sequence of the mut6 site, a U-rich element
located 24 nucleotides downstream from the major cleavage
site of sFlt-1 mRNA, suggested that the region is a possible
binding site for CstF (cleavage stimulation factor) [23]. The si-
gniﬁcantly decreased production of soluble-form RNA by the
mut6minigenemaybebecauseoftheeliminationofCstFbinding
to intron 13 (Figure 8). CstF64 (64-kDa subunit of CstF) is
essential for binding to the U-rich region, and up-regulation of
CstF64 induces preferential utilization of an upstream poly(A)
site [24,25]. In addition, Kubo et al. [26] have reported the
involvement of CFIM25 (25-kDa subunit of the cleavage factor
Im) in alternative poly(A)-site selection. However, both CstF64
and CFIM25 mRNA levels remained unchanged under hypoxia
(10–1% O2) (results not shown). These results suggest that
another mechanism might be involved in the regulation of
hypoxia-induced alternative 3
 -end processing of sFlt-1 mRNA.
hnRNP D overexpression affects alternative processing
of sFlt-1 mRNA
The mut6 site is composed of a 5-nucleotide stretch, AUUUA.
Similar sequences have been identiﬁed as binding sites for
several RNA-binding proteins, including hnRNP A2/B1, HuR
and hnRNP D [22]. To determine whether factors that bind
to the mut6 site can affect the alternative processing of sFlt-1
mRNA, we examined the effects of hnRNP D (chosen as a model
factor) overexpression because hnRNP D is known to bind to
the AUUUA motif. A lentiviral vector carrying human hnRNP D
cDNA was constructed, as described in the Experimental section,
andwasintroducedintoHMVECs.RT–PCRconﬁrmedhnRNPD
overexpression in transduced HMVECs (Figure 9A). Total RNAs
were isolated from the control and transduced HMVECs, and
endogenous sFlt-1 and mFlt-1 mRNA levels were examined by
RT–PCR. As shown in Figure 9(A), hnRNP D overexpression
signiﬁcantly decreased sFlt-1 mRNA levels. Real-time PCR
analysis conﬁrmed the decrease in sFlt-1 mRNA levels in hnRNP
D-overexpressing cells (Figure 9B).
Next, HMVECs were co-transfected with Flt-1 minigenes and
hnRNP D, and soluble- and membrane-form RNA levels were
evaluated by RT–PCR. As shown in Figures 9(C) and 9(D),
hnRNP D overexpression decreased the soluble-/membrane-form
RNA ratio to approximately 40% in the wild-type and mut2
minigenes. hnRNP D overexpression also decreased the soluble-/
membrane-form RNA ratio in the mut6 minigene (Figures 9C
and 9D). The mut6 mutant still produced a small amount of
soluble-form RNA (Figures 8B and 9C), suggesting that U-rich
sequences around the original AUUUA site may serve as low-
afﬁnity CstF64-binding sites [23]. Therefore it is assumed that
overexpressed hnRNP D competed with CstF64 in the 3
 -
end processing of sFlt-1 mRNA. These results suggest that
competition between CstF and a factor that can bind to the
mut6 site might possibly regulate alternative 3
 -end processing
of mRNA. However, it should be noted that mRNA levels of
hnRNP A2/B1, HuR and hnRNP D remained unchanged under
hypoxia (results not shown), suggesting that other factors or post-
translational modiﬁcations of RNA-binding proteins might be
involved in the regulation of this alternative processing.
DISCUSSION
In the present study, we have demonstrated that sFlt-1 expression
in HMVECs, the constituent of microvessels where angiogenesis
occurs, is down-regulated under hypoxia and this involves
the alternative 3
 -end processing of Flt-1 mRNA under these
conditions.
Although sFlt-1 (sVEGFR-1) is suggested to be involved in
both physiological and pathological angiogenesis [10–12,27],
the mechanisms by which sFlt-1 expression is regulated have
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Figure 9 Effects of hnRNP D overexpression on alternative processing in HMVECs
(A) Effects of hnRNP D overexpression on alternative processing of endogenous sFlt-1 mRNA. Total RNAs from HMVECs transfected with control and human hnRNP D lentiviral constructs were
analysed by RT–PCRwith human-speciﬁcprimersfor sFlt-1 and mFlt-1 mRNAs. (B) ThesFlt-1/mFlt-1 mRNA ratio. Relative mRNA levels werequantiﬁed by real-time RT–PCRusing the same RNAs
in (A), as described in the Experimental section. Values are means+ −S.D. (n=3). Statistical signiﬁcance was determined using a Student’s t test for unpaired data. ***P <0.001. (C) Effects of
hnRNP D overexpression on alternative processing of RNAs expressed by the Flt-1 minigene. Total RNAs from HMVECs co-transfected with the Flt-1 minigene and human hnRNP D were analysed
by RT–PCR. (D) The soluble/membrane RNA ratio from (C). Quantiﬁcation of the signal intensities of soluble-/membrane-form RNAs was performed using the ImageJ program.
not yet been fully clariﬁed. Available results regarding sFlt-
1 expression under hypoxia are conﬂicting. Xiong et al. [14]
have reported that hypoxia leads to increased sFlt-1 secretion in
HUVECs; however, other studies have demonstrated that sFlt-1
expression and secretion are not affected by hypoxia [15,16].
The discrepancy between the conclusions of previous studies
and our present study may be due to the difference between
microvasculature (HMVECs) and macrovasculature (HUVECs).
mFlt-1 was reported to be up-regulated by hypoxia in HUVECs
[28] and in MVECs derived from bovine corpus luteum and
eyes [29,30]. A consensus binding site for HIF-1 is within the
Flt-1 promoter [28]. In contrast, our present results show that
mFlt-1 expression in HMVECs remains unchanged or is slightly
decreased by hypoxia (Figures 1 and 2). In view of the marked
decrease in sFlt-1 expression in HMVECs under hypoxia, we
propose that sFlt-1 mRNA levels under these conditions are
selectively regulated at the level of alternative 3
 -end processing
of its pre-mRNA.
HIF-1 plays a central role during the response to hypoxia
[18]. We examined whether or not HIF-1 was involved in the
hypoxia-induced decrease in sFlt-1 mRNA levels in HMVECs
via the blockade of HIF-PHD that leads to HIF-1α degradation.
In contrast with hypoxia, a PHD inhibitor, DMOG, increased
both sFlt-1 and mFlt-1 mRNA levels at 50–100 μMD M O G
(equivalent to 1–2.5% O2), but the sFlt-1/mFlt-1 mRNA ratio
remained unchanged (Figure 4). These results indicated that HIF-
1 was not directly involved in the hypoxia-induced decrease in
sFlt-1 mRNA in HMVECs. Factors other than HIF-1 (probably as
yet unidentiﬁed hypoxia-regulated RNA-binding proteins) may
be involved in the regulation of alternative Flt-1 mRNA 3
 -end
processing under hypoxia.
VEGF stimulates EC proliferation, migration and tube
formation by binding to KDR (VEGFR-2) [31]. sFlt-1 has been
reported to function as a decoy receptor for VEGF, which
suppresses VEGF-induced signalling [7–10,12]. In the present
study, we report that sFlt-1 when overexpressed in HMVECs
attenuates VEGF-induced EC proliferation (Figure 5). These
results suggest that the hypoxia-induced decrease in sFlt-1
productionandthecorrespondingincreaseinVEGFexpressionin
HMVECs play an active role in EC proliferation under hypoxia.
Thus sFlt-1 may be an essential component involved in autocrine
regulation of angiogenesis.
In the present study, we also found cis-regulatory elements
involvedinsFlt-1mRNAprocessinginHMVECs.Weidentiﬁeda
majorprocessingsite(nucleotideposition112inintron13)ofsFlt-
1 mRNA produced in HMVECs. Mutational analyses of an Flt-1
minigene construct revealed that two non-contiguous AUUAAA
sequences act as the poly(A) signal (Figure 7) and that a U-rich
region 24 nucleotides downstream of the major cleavage site is
essential for the 3
 -end processing of sFlt-1 mRNA (Figure 8).
The position and sequence of the U-rich element suggest that
the region is a possible binding site for CstF [23]. However,
CstF64 and CFIM25 mRNA levels remained unchanged under
hypoxia (results not shown). On the other hand, overexpression
of hnRNP D, an RNA-binding protein that can bind to this U-
rich sequence, signiﬁcantly decreased endogenous sFlt-1 mRNA
levels, as well as the soluble/membrane RNA ratio expressed
from the minigene (Figure 9). This suggests that competition
between CstF and RNA-binding proteins that can bind to the U-
richelementmightpossiblyregulatealternative3
 -endprocessing
of sFlt-1 mRNA. However, mRNA levels of possible U-rich
element-binding proteins examined to date (hnRNP A0, hnRNP
A2/B1, HuR and hnRNP D) remained unchanged under hypoxia
(results not shown). We performed DNA microarray analysis
of gene expression in HMVECs cultured under hypoxia (1 and
2.5%O2)usinganAffymetrixGeneChip® array,butwereunable
to detect any RNA-binding protein transcripts whose expression
levels changed under these conditions (results not shown). These
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results suggest that post-translational modiﬁcations of RNA-
binding proteins might be involved in regulating Flt-1 mRNA
processing.
Althoughmorestudiesareneededtoclarifythetrans-regulatory
factors functioning on the cis-elements identiﬁed and their
regulation under hypoxia, the results of the present study have
revealed new aspects of sFlt-1 expression and function. We
believethatourpresentstudywillprovidenewcluesforclarifying
further the mechanisms involved in regulating angiogenesis and
for developing novel anti-angiogenesis therapeutic strategies for
treating cancer and other angiogenesis-related diseases.
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Table S1 Sequences of primers used for RT–PCR and site-directed mutagenesis
(a) Primers for RT–PCR
Gene Sequence Product size
sFlt-1 (sVEGFR-1) 5-ATGTGCCAAATGGGTTTCAT-3 352 bp
5-TTGGAGATCCGAGAGAAAACA-3
mFlt-1 (mVEGFR-1) 5-ATGCCACCTCCATGTTTGAT-3 317 bp
5-TAGATGGGTGGGGTGGAGTA-3
VEGF (VEGF-A) 5-GCCTCCGAAACCATGAACTTTCTGCTG-3 322 bp
5-TGGTGATGTTGGACTCCTCA-3
KDR (VEGFR-2) 5-GTGGGCTGATGACCAAGAAG-3 517 bp
5-TCACAAGGGTATGGGTTTGTC-3
hnRNP D 5-GATCCTAAAAGGGCCAAAGC-3 306 bp
5-CCACTGTTGCTGTTGCTGAT-3
β-Actin 5-CATCGAGCACGGCATCGTC-3 506 bp
5-CTCTTCTCCAGGGAGGAGC-3
Neomycin 5-AGACAATCGGCTGCTCTGAT-3 261 bp
5-ATACTTTCTCGGCAGGAGCA-3
(b) Primers for site-directed mutagenesis (mutated sites are underlined)
Primer name Sequence
PAmut1 5-CACAAAGTAATGTAAAACATCCCAGGACTCATT-3
5-ATGTTTTACATTACTTTGTGTGGTACAATC-3
PAmut2 5-AGGACTCATCCCAAAGTAACAGTTGTCTCATAT-3
5-ATGAGTCCTGGGATGTTTTACATTACTTTG-3
mut1 5-CTCCAGAAGAAAGAAATTACTTACAGAGGTGAG-3
5-GTAATTTCTTTCTTCTGGAGGATTTCTTCC-3
mut2 5-AGAAGAAAGAAATTACAATGTCAGGTGAGCACT-3
5-ATTGTAATTTCTTTCTTCTGGAGGATTTCT-3
mut3 5-TTTTCTCTCGGATCTCCAAAAAAAAAAGCACAA-3
5-TTTGGAGATCCGAGAGAAAACAGCCTTTTT-3
mut4 5-TCGGATCTCCAAATTTATTTGCACAAGGAATGA-3
5-TAAATTTGGAGATCCGAGAGAAAACAGCCT-3
mut5 5-AAGGACTCATTAAAAAGTAAGTCTTGTCTCATA-3
5-TTACTTTTTAATGAGTCCTTTAATGTTTTA-3
mut6 5-GTTGTCTCATATCATCTTGAAAAATTGTCAATG-3
5-TCAAGATGATATGAGACAACTGTTACTTTT-3
mut7 5-CATCTTGATTTATTGTCACTCAAGCTAACTTTC-3
5-AGTGACAATAAATCAAGATGATATGAGACA-3
mut8 5-TGTCACTGTTGCTAACTAAGAGGCTCGGAGGAG-3
5-AGTTAGCAACAGTGACAATAAATCAAGATG-3
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Table S2 Sequences of primers used for cloning of Flt-1 and hnRNP D
Restriction enzyme sites are underlined.
Use of primer Sequence Restriction enzyme Product size
sFlt-1 cDNA cloning 5-GAGAATTCGAACGAGAGGACGGACT-3 EcoRI 2157 bp
5-GAGCGGCCGCGAGTCCTTTAATGTTTTACATTAC-3 NotI
hnRNP D cloning 5-CGAATTCGCCACCATGTCGGAGGAGCAGTTCGG-3 EcoRI 893 bp
5-AGATCCTTGCGGCCGCTTAGTATGGTTTGTAGCTAT-3 NotI
Amplifying exon 12 and a part of intron 12 of Flt-1 5-AGCTCGAGATGGCTAGCACCTTGGTTGTGGCTGAC-3 XhoI 979 bp
5-GAACGCGTGATATCTCCCATGGCACAGA-3 MluI
Amplifying exon 13 and a part of intron 12 and 13 of Flt-1 5-GAACGCGTTGAGATCATGCCACAGCACT-3 MluI 1794 bp
5-GAGTCGACTGCATATGGGGAAAGTGGAC-3 SalI
Amplifying a part of intron 13 and exon 14 of Flt-1 5-GAGTCGACTGTGCCTCTGCCTCTTGAAT-3 SalI 777 bp
5-GAGCGGCCGCGGGGCTGATGAAAGATGAGA-3 NotI
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